Reimbursement and value assessment frameworks: ensuring patients’ access to asthma medicines in Ukraine
Journal Title: JOURNAL OF HEALTH POLICY & OUTCOMES RESEARCH - Year 2017, Vol 1, Issue 1
Abstract
Background. Health technology assessment (HTA) introduction and implementation for development of the National List of Essential Medicines (NLEM) took place in Ukraine in 2016 in the context of National Drug Policy until 2025. The study aimed to outline the reimbursement of medicines for asthma treatment, market access for innovative medicines, main steps of HTA development in the decision making process in Ukraine in line with the international requirements and future directions. Methods. Literature review was conducted examining legislation database and scientific publications on the study issues in Ukraine: epidemiology of asthma, reimbursement programs, HTA development, affordability of innovative medicines for asthma treatment, market analysis. The study was performed to investigate the practices, processes and policies of value assessment and their impact in Ukraine. Results. In 2016 a legal framework was developed for the elaboration of NLEM and procedures for reference pricing and reimbursement programs. HTA is used for the inclusion medicines on the list based on the applied evidence of quality, efficacy, effectiveness, safety and economic evaluations adhering to the Order of Ministry of Health (MoH). HTA implementation in 2016 consisted of legislation, HTA training for experts of Expert committee of MoH and development of NLEM. Reimbursement programs for cardiovascular diseases, type 2 diabetes (T2D), asthma have started in April 2017 due to the adopted regulations. Conclusions. HTA use in the decision-making in Ukraine will provide an access to innovative medicines for patients and transparent, consistent decision making process in assessing the health technologies for inclusion on regulatory lists and reimbursement programs.
Authors and Affiliations
Olha Zaliska, Oresta Pinyazhko, Roman Ilyk, Hryhoriy Irynchyn
Keywords
Related Articles
- EP ID EP326179
- DOI 10.7365/JHPOR.2017.1.5
- Views 71
- Downloads 0
Neoadjuvant treatment of HER2-positive breast cancer – pathological complete response (pCR) as a surrogate of long term outcomes in the context of regulatory guidelines and reimbursement recommendations.
Background: The vast heterogeneity of breast cancer (BC) patients, together with relatively long survival in the early stages of the disease, leads to methodological issues in designing clinical trials, particularly in c...
Contracts for providing publically funded outpatient medical services - criteria for tenders evaluation as a tool of health policy in Poland
he Polish health care system is essentially divided into three basic levels of service: basic health care, outpatient specialist care, hospital treatment. Since 2003 the payer is the National Health Fund. Medical facilit...
The assessment of the impact of thrombocytopenia symptoms on the patients’ daily activities with the use of TSIDAV vignette
Objective: Assessment of the impact of thrombocytopenia symptoms on patients’ daily activities using vignettes. Methods: Vignettes were used to collect information from adult patients and children’s caregivers in order...
Adoption of Real World Evidence in decision-making processes on public funding of drugs in Poland
Background: The aim of the study was to assess the use and impact of RWE in decision-making processes on public funding of drugs in Poland. Methods: The analysis was based on data from the Agency for Health Technology A...
Pharmaceutical Policies under Economic Crisis: The Greek case
Introduction: The purpose of this paper is to critically assess the Pharmaceutical reforms implemented in Greece before and during the economic crisis. The effects of the crisis are multiple in terms of GDP reduction, se...